The comparative effectiveness of surgery and radiation therapy for high-grade, clinically localized prostate cancer remains a seminal, open question in urologic oncology, with no randomized controlled trials to inform management.
Previous studies have investigated [18F]-fluorocholine (FCH) positron emission tomography with computed tomography (PET/CT) in primary staging of men with intermediate or high-risk prostate cancer and have generally shown high specificity and poor sensitivity.
Whilst there is a trend away from aggressive nonorgan sparing surgical treatments for malignant penile disease, a variety of penile preservation options exist but functional outcomes and patient reported outcomes (PROs) in this area are poorly reported to date.
Urothelial bladder cancer (UBC) patients ineligible to platinum-based chemotherapy can be treated with immune-checkpoint inhibitors (ICI) in Programmed Death Ligand 1 (PD-L1) positive cases. Although concordance exists between different PD-L1 assays, little is known on PD-L1 expression variability in matched UBC samples.
Atezolizumab, a programmed-death ligand-1 (PD-L1) inhibitor, is a novel treatment option for patients with metastatic urothelial cancer (mUC). Clinical prognostic factors, survival outcomes, and the safety of patients with mUC treated with atezolizumab, in a real-world setting, were investigated.
Neal Shore: Hi, everyone. Great to talk to you today. I’m Neal Shore and I’m the Medical Director of Carolina Urologic Research Center. What a pleasure to introduce the co-founders and innovators for the Advanced Prostate Cancer Consensus Conference, Silke Gillessen and Aurelius Omlin. They should not be strangers to anyone who has been monitoring […]
While existing guidelines can summarize the existing evidence and form treatment recommendations, there are many areas in the management of patients with advanced prostate cancer where: There is no available evidence from large prospective randomized trials The evidence is sparse or only low-level The existing evidence is conflicting or the interpretation of the evidence is […]
The diagnosis of penile cancer imparts life-changing implications for a patient, inflicting a burden of both oncological concern and anticipation of organ removal, distortion, or dysfunction. Whilst historically the treatment has been radical penectomy, the necessity for full penile amputation has been challenged in more recent times.1, 2 Organ-sparing surgery (OSS) has thus evolved. Whilst […]
Introduction: Hematuria can be a distressing and debilitating complication of urothelial carcinoma (UC) of the kidney for patients who are not candidates for surgery or ureteroscopic ablation. We retrospectively assessed the efficacy, tolerability, and safety of stereotactic body radiotherapy (SBRT) for controlling gross hematuria in this patient population.
San Francisco, CA (UroToday.com) — Astellas Pharma Inc. announced that the European Commission (EC) has approved an additional indication for the oral once-daily therapy XTANDI™ (enzalutamide) for adult men with metastatic hormone-sensitive prostate cancer (mHSPC, also known as metastatic castration-sensitive prostate cancer or mCSPC). Men diagnosed with mHSPC tend to have a poor prognosis, with a […]
